Why Drug Approval Takes So Long: The Pipeline Has Been Clogged for 20 Years

Twenty years ago it took 12 years after the average drug’s original patent was filed to go through the approval pipeline to eventually be launched. Today, however, it takes—12 years. No change, in other words.  That’s the finding in a report issued Monday by QuintilesIMS Institute, in consultation with STAT Plus that’s raised eyebrows. The silver lining is that new drugs are moving faster to market after they get final approval than they did during the Great Recession. There are outcomes and financial reasons that the pipeline needs to be speeded up, STAT Plus reports. The faster a drug can get through the pipeline, the faster patients who need the medications can be helped and the sooner drug companies can start to see a return on investment in research and development.   

Murray Aitken, executive director of QuintilesIMS Institute, tells STAT Plus that there are two reasons for the pipeline backup. The FDA wants better evidence to get drugs approved and “we haven’t seen as much progress in revolutionizing the approach to clinical development that we might have expected 20 years ago.”

Also, two decades ago companies could expect 14 years of patent protection for their new drugs; today it’s 12 years. “All of this helps to explain why drug prices have soared in recent years,” STAT Plus reports. “Companies that cannot quickly push their drugs through the pipeline get a return on their investment later, creating incentive to charge more to make up for lost time. That also translates into fewer years on the market before a patent expires, which may also drive companies to charge more to squeeze the most out of the time they have to reap big profits before the floodgates open to generic competition.”

Source: QuintilesIMS Institute, “Lifetime Trends in Biopharmaceutical Innovation: Recent Evidence and Implications” 

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.